Paris-based biotech startup Tridek-One has raised €16 million in funding to speed up its research and development of CD31 agonists to restore the immune balance. The round was led by the Swiss VC Pureos Bioventures with the participation of new investors Bpifrance, through its InnoBio2 fund, and Bioqube Ventures and historical investors AdBio and Advent Life Sciences.
Founded in 2018 by Dr. Giuseppina Caligiuri and Pr. Antonino Nicoletti, the startup develops immune checkpoint agonists to restore the immune balance in patients living with auto-immune diseases.
Going forward, the funds will primarily be used to identify development candidates against auto-immune diseases, to conduct IND-enabling studies and to further build the organisation. The company had earlier raised €3 million in 2019.
Laurence de Schoulepnikoff, CEO of Tridek-One said: “We plan to reach important preclinical milestones and build a biotech organisation for the treatment of auto-immune diseases.”
Klaus Breiner, managing partner at Pureos Bioventures added: “There is still an important, unsatisfied medical need in many auto-immune diseases. Agonising immune inhibitory receptors like CD31 have the potential to rebalance the immune system without being more broadly immunosuppressive. We are excited to further translate this concept with Tridek-One through its discovery and preclinical stages.”